Navigation Links
Dipyrone may Treat Headaches -- but Use With Caution

The controversial drug dipyrone can treat acute headaches, but patients should be warned of the risk of// potentially serious blood disorders (or "dyscrasias"), concluded a Cochrane Review team. Furthermore, most of the studies used in reaching this conclusion involved intravenous infusions of the drug, making it expensive and complex to deliver.

Dipyrone is a non-opioid painkiller that was launched in Germany in 1922 but was later banned from many countries including the USA and UK because of evidence that it might cause life-threatening blood disorders such as agranulocytosis. It is, however, a popular analgesic in many parts of the world including South America, India, South Africa, Russia and several European countries. Oral doses can be bought over the counter in Brazil and Spain.

A group of Cochrane Researchers set out to evaluate whether dipyrone was effective and safe for acute primary headaches in adults and children.

They identified four trials that involved 636 adults. None involved children. Three of the studies used intravenous dipyrone.

Taken together the evidence indicates that dipyrone is effective in treating episodic tension-type headaches and migraine in adults. The sample size, however, was too small to make any assessment of the medicine's safety.

"Given that many effective and more easily administered therapies are available, patients and clinicians will need to consider whether and in what circumstances the benefits of treatment are worth the time, trouble and expense of intravenous administration," says Dr Rebecca Gray, a Cochrane Editor who worked closely with the project.

If used, "patients should be well informed about the risk of blood dyscrasias," she adds.

Source-Eurekalert/V
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. New FDA Approved Drug To Treat Migraine
4. Treatment for Menieres disease
5. Treatment for pre-menstrual syndrome is ineffective
6. Angiotensin-II-receptor blockers - Treat kidney failure
7. Cipro Has Cheaper Cousins to Treat Anthrax
8. Better Treatment for obesity
9. Gene Treatment for Heart Disease
10. Cyclosporin A Treats Leukemia Complications
11. New Way To Treat Lupus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/25/2017)... OK (PRWEB) , ... July 25, 2017 , ... ... proud to announce the launch of their partnership to provide the Pharmacist ... the first pharmacy-focused platform in the country with the ability to develop the ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... ATM provider in the United States, today announced its partnership with financial technology ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
Breaking Medicine News(10 mins):
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
Breaking Medicine Technology: